| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.5 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.041 | 0.5 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.024 | 0.5 |